Companies: 10,795·Total market cap: $144.5T
Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRVFOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$323
P/E Ratio—
52W High$0.0002
52W Low$0.0001
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Nabriva Therapeutics plc (NBRVF) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001641640 · NBRVF · OTC · as of Jun 10, 2026

Filing snapshot

695
Total Filings
15-12G
Latest Form
2023-10-25
Most Recent
2023
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001641640 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-04-17
Fiscal Year End
Apr 17, 2023
Accession No.
0001558370-23-006062
Primary Document
nbrv-20221231x10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001641640 · Accession 0001558370-23-006062

Latest Key Filings

6-KQuarterly Report
6-K
2016-12-20
View 6-K on SEC
8-KCurrent Report
FORM 8-K
2023-07-31Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2023-10-25
View
EFFECTEFFECT
EFFECT
2023-10-24
View
POS AMPOS AM
POS AM
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
S-8 POSS-8 POS
S-8 POS
2023-10-20
View
10-QQuarterly Report
10-Q
2023-10-19
View
25-NSE25-NSE
25-NSE
2023-09-08
View
NT 10-QNT 10-Q
NT 10-Q
2023-08-14
View
8-KCurrent Report
FORM 8-K
2023-07-31
View
Showing 1–15 of 370 filingsForm 4 / 144 hidden· 695 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001641640  |  Exchange: OTC · Healthcare

Nabriva Therapeutics plc (OTC: NBRVF) has submitted 695 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2023. As a Healthcare sector company with CIK 0001641640, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Nabriva Therapeutics plc's most comprehensive regulatory disclosure. The most recent Nabriva Therapeutics plc 10-K was filed on 2023-04-17 for fiscal year ending 2023. Historical NBRVF 10-K annual reports are available from 2015 through 2023.

Investors researching Nabriva Therapeutics plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10
Related Companies SEC Filings — Healthcare
ELOX SEC Filings →MODC SEC Filings →BIOCQ SEC Filings →VRCI SEC Filings →MICRD SEC Filings →OMDD SEC Filings →HTGMQ SEC Filings →MDVLQ SEC Filings →
→ NBRVF Financials→ NBRVF Earnings→ NBRVF Insider Trades

Frequently Asked Questions

NBRVF SEC Filings · 8 questions

Nabriva Therapeutics plc (NBRVF) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 695 filings and access original documents at no cost. Nabriva Therapeutics plc's CIK is 0001641640.

NBRVF SEC filingsNabriva Therapeutics plc SEC documentsfind NBRVF 10-K